Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9Y6W3
UPID:
CAN7_HUMAN
Alternative names:
PalB homolog
Alternative UPACC:
Q9Y6W3
Background:
Calpain-7, also known as PalB homolog, is a unique member of the calpain family characterized by its calcium-regulated non-lysosomal thiol-protease activity. Unlike other calpains, Calpain-7's specific functions and mechanisms of action are less understood, making it a subject of ongoing research.
Therapeutic significance:
Understanding the role of Calpain-7 could open doors to potential therapeutic strategies. Its unique enzymatic activity suggests it may play a pivotal role in cellular processes, offering new avenues for drug discovery.